The ME&MG Digital Solution for Autonomous Assessment of Myasthenia Gravis
NCT ID: NCT05564936
Last Updated: 2025-04-11
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
NA
144 participants
INTERVENTIONAL
2024-01-24
2026-09-24
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
ME\&MG contains digital active tests for the assessment of ptosis, breathing, dysarthria, upper- and lower-limb (arms and legs) weakness, treatment follow-up, and validated e-questionnaires related to daily activities, pain, fatigue, sleep, and depression disorders.
The objectives of this study are to validate the accuracy, reliability and reproducibility of the unsupervised at-home self-assessment of symptoms on the patient's smartphone with ME\&MG versus the standard in-clinic testing, as well as to evaluate the safety of the solution, its usability and satisfaction.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Descriptive Analysis of Real-world Data Collected with ME&MGopen
NCT05566964
Multi-Modal Monitoring of Disease Symptoms in Myasthenia Gravis
NCT07224386
Expediting Myasthenia Gravis (MG) Diagnostic Evaluation: A Novel, Proof-of-Concept for Undiagnosed, Symptomatic Patients That Uses Social Media Targeting and Self-Assessment
NCT06381284
Holistic Assessment and Remote Digital MONitoring of mYasthenia Gravis Via MyoSense 360
NCT07323316
Help Build an A.I. Model to Predict Myasthenia Gravis Symptom Patterns and Flares
NCT04590716
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Deficits are measured using validated clinical scales such as the Quantitative Myasthenia Gravis score (QMG) QMG, Myasthenia Gravis Composite Score (MCS), Myasthenia Gravis Activities of Daily Living score (MG-ADL), etc., Unfortunately, this type of assessment might require expensive material, time, and personnel training, which make MG assessment difficult for clinicians in routine care.
Research on the matter has highlighted the importance of Patient-Reported Outcomes (PROs), composite measures of disease severity and quality-of-life measurements. This has led to the development of a number of tools for the self-assessment of PROs with validated questionnaires. However, there is no tool that overcomes the constraints of standard tests such as the QMG while allowing for the collection of objective data and PROs between visits.
ME\&MG is a standalone software (digital solution) running on patients smartphones, connected to a web portal for physicians. It is intended to be used as an unsupervised digital self-assessment tool for the monitoring of disabilities in patients living with MG.
ME\&MG contains digital active tests for the assessment of ptosis, breathing, dysarthria, upper- and lower-limb (arms and legs) weakness, treatment follow-up, and validated e-questionnaires related to daily activities, pain, fatigue, sleep, and depression disorders.
The objectives of this study are to validate the accuracy, reliability and reproducibility of the unsupervised at-home self-assessment of symptoms on the patient's smartphone with ME\&MG versus the standard in-clinic testing, as well as to evaluate the safety of the solution, its usability and satisfaction.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
SINGLE_GROUP
OTHER
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
MG patients
MG patients will perform 3 in-clinic visits and use the ME\&MG app at-home during 12 months
ME&MG mobile application
ME\&MG is a standalone software (digital solution) running on patients smartphones, connected to a web portal for physicians. It is intended to be used as an unsupervised digital self-assessment tool for the monitoring of disabilities in patients living with MG.
Healthy volunteers
Healthy volunteers will perform one in-clinic visit and will use the app at-home once
ME&MG mobile application
ME\&MG is a standalone software (digital solution) running on patients smartphones, connected to a web portal for physicians. It is intended to be used as an unsupervised digital self-assessment tool for the monitoring of disabilities in patients living with MG.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
ME&MG mobile application
ME\&MG is a standalone software (digital solution) running on patients smartphones, connected to a web portal for physicians. It is intended to be used as an unsupervised digital self-assessment tool for the monitoring of disabilities in patients living with MG.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Diagnosed with gMG at screening with generalized muscle weakness meeting the clinical criteria for diagnosis of MG, as defined by the MGFA Clinical Classification Class II, III, or IV, and likely not in need of a respirator for the duration of the study, as judged by the investigator
* With positive serologic testing for anti-AChR autoantibody at screening
* Have read the information sheet and signed the informed consent form
* Own a personal smartphone which software version is above 13 for IOS and 8 for Android included
* Able to use a smartphone
* Able to read language in which the mobile application is available (French, English, Spanish) and able to understand pictograms
Exclusion Criteria
* Subjects having initiated FcRn inhibitor therapy within the four weeks preceding screening
* Known medical or psychological condition(s) or risk factor(s) that, as judged by the investigator, might interfere with the subject's full participation in the study, pose any additional risk for the subject, or confound the assessment of the subject or outcome of the study.
* Pregnant and nursing women
* Person under guardianship or curatorship
* Current drugs or/and alcohol abuse that could influence performance on the tests, as judged by the investigator
* Participant included in another ME\&MG clinical study
* Participant has participated in another clinical study within the previous 30 days of screening or is currently participating in another study that, in the opinion of the Investigator, might interfere with the subject's full participation in the study or confound the assessment of the subject or outcome of the study.
18 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Ad scientiam
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of Colorado Denver
Aurora, Colorado, United States
University of Florida Health
Jacksonville, Florida, United States
HealthParterns Institute
Bloomington, Indiana, United States
Indiana University Health
Indianapolis, Indiana, United States
University of Kentucky
Lexington, Kentucky, United States
Neurological Associates of Long Island, P.C.
Lake Success, New York, United States
Duke University
Durham, North Carolina, United States
OHSU
Portland, Oregon, United States
Thomas Jefferson University
Philadelphia, Pennsylvania, United States
The University of Tennessee Medical Center
Knoxville, Tennessee, United States
Vanderbilt Health
Nashville, Tennessee, United States
Hôpital Raymond Poincaré
Garches, , France
CHU Grenoble
Grenoble, , France
Hôpital Salengro
Lille, , France
CHRU Nancy
Nancy, , France
CHU Nantes
Nantes, , France
Pitié-Salpêtrière
Paris, , France
CHU de Strasbourg - Hôpital de Hautepierre
Strasbourg, , France
CHU Toulouse
Toulouse, , France
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
DOMYA
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.